Acquired amegakaryocytic thrombocytopenia after durvalumab administration

Immune checkpoint inhibitors (ICIs), despite their ability to potentiate antitumor T-cell responses, may cause various immune-related adverse events. Most cases of thrombocytopenia induced by ICIs have revealed a pathophysiologic mechanism of immune thrombocytopenia with increased platelet destructi...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Argitaratua izan da:J Clin Exp Hematop
Egile Nagusiak: Suyama, Takahiro, Hagihara, Masao, Kubota, Naoto, Osamura, Yoshiyuki, Shinka, Yoko, Miyao, Naoki
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: JSLRT 2021
Gaiak:
Case Report
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC8053569/
https://ncbi.nlm.nih.gov/pubmed/33431742
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3960/jslrt.20047
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak